Kingdom of Saudi Arabia King Saudi University (034) p.o. Box 7805 Riyadh 11472 Tel: +966 11 467 00 11 Fax: +96611 467 19 92 http://medicalcity.ksu.edu.sa

المملكة العربية السعودية جامعة الملك سعود (٣٤) ص.ب م ٧٨٠ الرياض ٧٢٤ا مانف: ١١.. ٢٧٤ ١٢٦٢٩ فاكس: ٩٩٢ ١٣٤٢



المدينة الطبية الجامية

22.07.2019 (19.11.1440) Ref. No. 19/0812/IRB

To:

Ms. Sama Alsulihem

Department of Public Health

King Saud University College of Medicine King Saud University Medical City Email: salsulaihem@hotmail.com

Principal Investigator

CC:

Dr. Hala Alhodaib

Co-Investigator

Subject:

Approval of Research Project No. E-19-4077

Study Title:

"Factors Influencing the Effectiveness of Using Continuous Glucose Monitoring (CGM)

On Glycemic Control among Type 1 Diabetes (T1D) In Saudi Arabia"

Type of Review:

Expedite

Date of Approval: Date of Expiry: 22 July 2019 22 July 2020

Dear Ms. Sama Alsulihem,

I am pleased to inform you that your above-mentioned research project submitted to the IRB was reviewed and approved on 22 July 2019 (11 Dhul Al-Qadah 1440). You are now granted permission to conduct this study given that your study does not disclose participant's identity and poses no risk to the patients.

As principal investigator, you are required to abide by the rules and regulations of the Kingdom of Saudi Arabia and the research policies and procedures of the KSU IRB. If you make any changes to the protocol during the period of this approval, you must submit a revised protocol to the IRB for approval prior to implementing the changes. Please quote the project number shown above in any future correspondence or follow-ups related to this study.

This approval is for a period of one (1) year commencing from the date of this letter. If you wish to have your protocol approved for continuation, please submit a completed request for reapproval of an approved protocol form (KSU-IRB 017E) at least 30 days before the expiry date. Failure to receive approval for continuation before the expiration date will result in automatic suspension of the approval of this protocol on the expiration date. Information collected following suspension is unapproved research and can never be reported or published as research data.

We wish you success in your research and request you to keep the IRB informed about the progress and final outcome of the study in a regular basis. If you have any question, please feel free to contact me.

Thank you!

Sincerely yours,

Prof. Abdulrahman Alsultan

Chairman of IRB

Health Sciences Colleges Research on Human Subjects

King Saud University College of Medicine

P. O. B ox 7805 Riyadh 11472 K.S.A.

Email: aalsultanı@ksu.edu.sa

braeze Mitutional

pay



Prince Sultan Military Medical City, Scientific Research Center P.O. Box 7897, Riyadh, 11159 Kingdom of Saudi Arabia Research Ethics Committee HP-01-R079

July 21, 2019

Sama Al-sulaihem, Pharmacy Supervisor, PSCC

RE: Factors influencing the effectiveness of using continuous glucose monitoring (CGM) on glycaemic control among type 1 diabetes (T1D) in Saudi Arabia.

Sama Al-sulaihem., Hala Alhodaib

This is in reference to your submitted proposal which has been reviewed by the appointed member of the committer through an expedited review process. On the recommendation of the board of review in the ethical aspects of the proposal, Research Ethics Committee is pleased to approve and grant permission to conduct your study. Your Research protocol has been documented under

Project No:

1226

Date Approved:

21 July

Series of:

2019

Kindly Quote the project number indicated herein in all transactions and communications. You are advised to submit a report in relation to this research scheme to update the committee of its progress.

Also please note that this approval is valid only one year commencing from the date of this letter. I trust your research scheme provides fruitful and beneficial to the Prince Sultan Military Medical City and its affiliated health centers.

Best Regards,

Dr. Nawaf Alkhayat

Chairman, Research Ethics Committee